(-)-epigallocatechin 3-gallate multiple interactions ISO RGD:1318224 6480464 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SGO2 mRNA CTD PMID:22079256 1,1,1-Trichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)ethane decreases expression ISO RGD:1318224 6480464 o, p'-DDT results in decreased expression of SGO2 mRNA CTD PMID:18204070 1,1-dichloroethene increases expression ISO RGD:1318225 6480464 vinylidene chloride results in increased expression of SGO2A mRNA CTD PMID:26682919 1-naphthyl isothiocyanate increases expression EXP 6480464 1-Naphthylisothiocyanate results in increased expression of SGO2 mRNA CTD PMID:30723492 17beta-estradiol increases expression ISO RGD:1318224 6480464 Estradiol results in increased expression of SGO2 mRNA CTD PMID:19167446 2,3,7,8-tetrachlorodibenzodioxine affects expression ISO RGD:1318224 6480464 Tetrachlorodibenzodioxin affects the expression of SGO2 mRNA CTD PMID:22574217 2,3,7,8-tetrachlorodibenzodioxine decreases expression EXP 6480464 Tetrachlorodibenzodioxin results in decreased expression of SGO2 mRNA CTD PMID:32109520 2,3,7,8-tetrachlorodibenzodioxine affects expression ISO RGD:1318225 6480464 Tetrachlorodibenzodioxin affects the expression of SGO2A mRNA CTD PMID:26377647 2-methylcholine affects expression ISO RGD:1318224 6480464 beta-methylcholine affects the expression of SGO2 mRNA CTD PMID:21179406 4,4'-sulfonyldiphenol increases expression ISO RGD:1318224 6480464 bis(4-hydroxyphenyl)sulfone results in increased expression of SGO2 mRNA CTD PMID:27685785 4-hydroxynon-2-enal decreases expression ISO RGD:1318225 6480464 4-hydroxy-2-nonenal results in decreased expression of SGO2 mRNA CTD PMID:19191707 acetamide increases expression EXP 6480464 acetamide results in increased expression of SGO2 mRNA CTD PMID:31881176 acrylamide decreases expression EXP 6480464 Acrylamide results in decreased expression of SGO2 mRNA CTD PMID:28606764 aflatoxin B1 affects expression ISO RGD:1318224 6480464 Aflatoxin B1 affects the expression of SGO2 protein CTD PMID:20106945 aflatoxin B1 decreases methylation ISO RGD:1318224 6480464 Aflatoxin B1 results in decreased methylation of SGO2 gene CTD PMID:27153756 arsane affects methylation ISO RGD:1318224 6480464 Arsenic affects the methylation of SGO2 gene CTD PMID:25304211 arsenic atom affects methylation ISO RGD:1318224 6480464 Arsenic affects the methylation of SGO2 gene CTD PMID:25304211 azathioprine decreases expression ISO RGD:1318224 6480464 Azathioprine results in decreased expression of SGO2 mRNA CTD PMID:22623647 benzo[a]pyrene decreases expression ISO RGD:1318224 6480464 Benzo(a)pyrene results in decreased expression of SGO2 mRNA CTD PMID:21632981 benzo[a]pyrene increases expression ISO RGD:1318225 6480464 Benzo(a)pyrene metabolite results in increased expression of SGO2A mRNA CTD PMID:32553695 benzo[a]pyrene affects methylation ISO RGD:1318224 6480464 Benzo(a)pyrene affects the methylation of SGO2 promoter CTD PMID:27901495 benzo[a]pyrene diol epoxide I decreases expression ISO RGD:1318224 6480464 7 more ... CTD PMID:19150397 , PMID:20382639 bisphenol A decreases expression ISO RGD:1318224 6480464 bisphenol A results in decreased expression of SGO2 mRNA CTD PMID:19490990 , PMID:29275510 bisphenol A increases methylation EXP 6480464 bisphenol A results in increased methylation of SGO2 gene CTD PMID:28505145 bisphenol A decreases expression EXP 6480464 bisphenol A results in decreased expression of SGO2 mRNA CTD PMID:25181051 , PMID:30816183 bisphenol A increases expression ISO RGD:1318224 6480464 bisphenol A results in increased expression of SGO2 protein CTD PMID:23142537 buta-1,3-diene increases expression ISO RGD:1318225 6480464 1, 3-butadiene results in increased expression of SGO2A mRNA CTD PMID:29038090 cadmium dichloride decreases expression ISO RGD:1318225 6480464 Cadmium Chloride results in decreased expression of SGO2 mRNA CTD PMID:24982889 calcitriol decreases expression ISO RGD:1318224 6480464 Calcitriol results in decreased expression of SGO2 mRNA CTD PMID:21592394 calcitriol multiple interactions ISO RGD:1318224 6480464 [Testosterone co-treated with Calcitriol] results in decreased expression of SGO2 mRNA CTD PMID:21592394 carbon nanotube increases expression ISO RGD:1318225 6480464 Nanotubes, Carbon analog results in increased expression of SGO2 mRNA, Nanotubes, Carbon results in increased expression of SGO2 mRNA CTD PMID:25554681 cisplatin decreases expression ISO RGD:1318224 6480464 Cisplatin results in decreased expression of SGO2 mRNA CTD PMID:27594783 copper atom increases expression EXP 6480464 Copper results in increased expression of SGO2 mRNA CTD PMID:30556269 copper(0) increases expression EXP 6480464 Copper results in increased expression of SGO2 mRNA CTD PMID:30556269 copper(II) sulfate decreases expression ISO RGD:1318224 6480464 Copper Sulfate results in decreased expression of SGO2 mRNA CTD PMID:19549813 coumestrol increases expression ISO RGD:1318224 6480464 Coumestrol results in increased expression of SGO2 mRNA CTD PMID:19167446 coumestrol multiple interactions ISO RGD:1318224 6480464 [Coumestrol co-treated with 2 more ... CTD PMID:19167446 cyclosporin A decreases expression ISO RGD:1318224 6480464 Cyclosporine results in decreased expression of SGO2 mRNA CTD PMID:20106945 more ... dichloroacetic acid increases expression ISO RGD:1318225 6480464 Dichloroacetic Acid results in increased expression of SGO2A mRNA CTD PMID:28962523 dicrotophos decreases expression ISO RGD:1318224 6480464 dicrotophos results in decreased expression of SGO2 mRNA CTD PMID:28302478 doxorubicin decreases expression ISO RGD:1318224 6480464 Doxorubicin results in decreased expression of SGO2 mRNA CTD PMID:29803840 Enterolactone multiple interactions ISO RGD:1318224 6480464 [Coumestrol co-treated with 2, 3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of SGO2 mRNA CTD PMID:19167446 folic acid multiple interactions ISO RGD:1318224 6480464 [Folic Acid deficiency co-treated with Methotrexate] results in decreased expression of SGO2 mRNA CTD PMID:24657277 formaldehyde decreases expression ISO RGD:1318224 6480464 Formaldehyde results in decreased expression of SGO2 mRNA CTD PMID:23649840 fragrance increases expression ISO RGD:1318224 6480464 Perfume results in increased expression of SGO2 mRNA CTD PMID:24768652 furan decreases expression EXP 6480464 furan results in decreased expression of SGO2 mRNA CTD PMID:25539665 hydrogen peroxide affects expression ISO RGD:1318224 6480464 Hydrogen Peroxide affects the expression of SGO2 mRNA CTD PMID:20044591 irinotecan decreases expression ISO RGD:1318224 6480464 Irinotecan analog results in decreased expression of SGO2 mRNA CTD PMID:18927307 leflunomide decreases expression ISO RGD:1318224 6480464 leflunomide results in decreased expression of SGO2 mRNA CTD PMID:28988120 lucanthone decreases expression ISO RGD:1318224 6480464 Lucanthone results in decreased expression of SGO2 mRNA CTD PMID:21148553 methotrexate multiple interactions ISO RGD:1318224 6480464 [Folic Acid deficiency co-treated with Methotrexate] results in decreased expression of SGO2 mRNA CTD PMID:24657277 methotrexate decreases expression ISO RGD:1318224 6480464 Methotrexate results in decreased expression of SGO2 mRNA CTD PMID:24657277 methylparaben decreases expression ISO RGD:1318224 6480464 methylparaben results in decreased expression of SGO2 mRNA CTD PMID:31745603 N-methyl-4-phenylpyridinium decreases expression ISO RGD:1318224 6480464 1-Methyl-4-phenylpyridinium results in decreased expression of SGO2 mRNA CTD PMID:24810058 N-Nitrosopyrrolidine decreases expression ISO RGD:1318224 6480464 N-Nitrosopyrrolidine results in decreased expression of SGO2 mRNA CTD PMID:32234424 ozone multiple interactions ISO RGD:1318225 6480464 [NOTCH3 gene mutant form affects the susceptibility to Ozone] which affects the expression of SGO2 mRNA CTD PMID:25658374 paracetamol increases expression ISO RGD:1318224 6480464 Acetaminophen results in increased expression of SGO2 mRNA CTD PMID:22230336 phenobarbital multiple interactions ISO RGD:1318225 6480464 NR1I3 protein affects the reaction [Phenobarbital results in increased expression of SGO2 mRNA] CTD PMID:19482888 phenobarbital increases expression ISO RGD:1318225 6480464 Phenobarbital results in increased expression of SGO2 mRNA CTD PMID:19482888 , PMID:23091169 pirinixic acid increases expression ISO RGD:1318225 6480464 pirinixic acid results in increased expression of SGO2 mRNA CTD PMID:20813756 pirinixic acid multiple interactions ISO RGD:1318224 6480464 [pirinixic acid binds to and results in increased activity of PPARA protein] which results in increased expression of SGO2 mRNA CTD PMID:19710929 potassium chromate multiple interactions ISO RGD:1318224 6480464 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SGO2 mRNA CTD PMID:22079256 potassium chromate decreases expression ISO RGD:1318224 6480464 potassium chromate(VI) results in decreased expression of SGO2 mRNA CTD PMID:22079256 progesterone decreases expression ISO RGD:1318224 6480464 Progesterone results in decreased expression of SGO2 mRNA CTD PMID:21795739 quercetin decreases expression ISO RGD:1318224 6480464 Quercetin results in decreased expression of SGO2 mRNA CTD PMID:21632981 resveratrol multiple interactions ISO RGD:1318224 6480464 [Coumestrol co-treated with resveratrol] results in increased expression of SGO2 mRNA CTD PMID:19167446 resveratrol increases expression ISO RGD:1318224 6480464 resveratrol results in increased expression of SGO2 mRNA CTD PMID:19167446 rotenone decreases expression ISO RGD:1318224 6480464 Rotenone results in decreased expression of SGO2 mRNA CTD PMID:29955902 rotenone decreases expression EXP 6480464 Rotenone results in decreased expression of SGO2 mRNA CTD PMID:28374803 silver atom decreases expression ISO RGD:1318225 6480464 Silver results in decreased expression of SGO2A mRNA CTD PMID:27131904 silver(0) decreases expression ISO RGD:1318225 6480464 Silver results in decreased expression of SGO2A mRNA CTD PMID:27131904 sodium arsenite increases expression ISO RGD:1318224 6480464 sodium arsenite results in increased expression of SGO2 mRNA CTD PMID:29301061 sulforaphane increases expression ISO RGD:1318224 6480464 sulforafan results in increased expression of SGO2 mRNA CTD PMID:31838189 sunitinib decreases expression ISO RGD:1318224 6480464 Sunitinib results in decreased expression of SGO2 mRNA CTD PMID:31533062 testosterone decreases expression ISO RGD:1318224 6480464 Testosterone results in decreased expression of SGO2 mRNA CTD PMID:21592394 testosterone multiple interactions ISO RGD:1318224 6480464 [Testosterone co-treated with Calcitriol] results in decreased expression of SGO2 mRNA CTD PMID:21592394 tetrachloromethane increases expression ISO RGD:1318225 6480464 Carbon Tetrachloride results in increased expression of SGO2A mRNA CTD PMID:31919559 trimellitic anhydride increases expression ISO RGD:1318225 6480464 trimellitic anhydride results in increased expression of SGO2 mRNA CTD PMID:19042947 troglitazone decreases expression ISO RGD:1318224 6480464 troglitazone results in decreased expression of SGO2 mRNA CTD PMID:19140230 valproic acid affects expression ISO RGD:1318224 6480464 Valproic Acid affects the expression of SGO2 mRNA CTD PMID:25979313 valproic acid decreases methylation ISO RGD:1318224 6480464 Valproic Acid results in decreased methylation of SGO2 gene CTD PMID:29154799 valproic acid decreases expression ISO RGD:1318224 6480464 Valproic Acid results in decreased expression of SGO2 mRNA CTD PMID:23179753 , PMID:27188386 vorinostat increases expression ISO RGD:1318224 6480464 vorinostat results in increased expression of SGO2 mRNA CTD PMID:27188386 
Gene-Chemical Interaction Annotations
